产地 | 进口/国产 |
保存条件 | 低温冷藏 |
品牌 | 上海富雨 |
货号 | FY-24JY697 |
用途 | 科研 |
组织来源 | RPMI1640 ??培养基 ;10%胎牛血清 ;1%双抗 |
细胞形态 | 见详情 |
是否是肿瘤细胞 | |
保质期 | 见详情 |
器官来源 | 见详情 |
免疫类型 | 见详情 |
品系 | 见详情 |
生长状态 | 见详情 |
物种来源 | 见详情 |
包装规格 | 1×10?cells/T25或1mL冻存管 |
是否进口 | 是 |
CTLA4 Aad and T cell-based adoptive cell therapies are eklective for patients with various cancers. However, response rates of ICI monotherapies are still limited due to lack of immunogenic antigens and various immune-resistant pkchanisms. The latter includes adaptive immune resistance that is caused by anti-tumor T cells (e.g. PD-L1 induced by IFN-γ from T cells) and primary immune resistance that is caused by cancer cells (e.g. immunosuppressive cytokines